Kinase inhibitors: Vice becomes virtue

In this issue of Cancer Cell, Fan and coworkers describe a novel inhibitor of PI3 kinase (PI3K) that potently interferes with the growth of glioma cells. They show that the efficacy of this inhibitor results from dual, synergistic activity against the p110α subunit of PI3K and against TOR. Although...

Full description

Saved in:
Bibliographic Details
Published in:Cancer cell 2006-05, Vol.9 (5), p.327-328
Main Authors: Vogt, Peter K., Kang, Sohye
Format: Article
Language:English
Subjects:
Animals
Humans
Neoplasms - drug therapy
Neoplasms - enzymology
Neoplasms - pathology
Phosphatidylinositol 3-Kinases - antagonists & inhibitors
Phosphatidylinositol 3-Kinases - metabolism
Protein Kinase Inhibitors - pharmacology
Protein Kinase Inhibitors - therapeutic use
Substrate Specificity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this issue of Cancer Cell, Fan and coworkers describe a novel inhibitor of PI3 kinase (PI3K) that potently interferes with the growth of glioma cells. They show that the efficacy of this inhibitor results from dual, synergistic activity against the p110α subunit of PI3K and against TOR. Although p110α and TOR belong to the same signaling pathway, they both must be inactivated because of the need to silence the regulatory feedback loop that remains unaffected by monospecific inhibitors. The new PI3K inhibitor achieves the effects of combination therapy as a single agent by fortuitously hitting two critical targets.
ISSN:1535-6108
1878-3686
DOI:10.1016/j.ccr.2006.05.002